Infratil (ASX:IFT, NZE:IFT) said CDC's valuation rose 7.2% over the three months to March 31, reflecting an increase of AU$1 billion from Dec. 31, 2025, to AU$15 billion, according to a Wednesday filing with the New Zealand bourse.
The company's 49.72% stake in CDC is now valued at AU$7.45 billion, up from AU$6.95 billion as of Dec. 31, 2025, the filing said.
The uplift reflects CDC's expanding pipeline of operating and planned capacity, alongside a successful AU$500 million equity raise, in which Infratil contributed AU$250 million, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments